logo
Plus   Neg
Share
Email

StemCells Announces Positive Interim Data From Spinal Cord Injury Trial

StemCells Inc. (STEM) announced that interim six-month data from the first patient cohort in the company's Phase I/II clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. The third patient remains stable.

The trial represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury.

The company stated that Patients in the study's first cohort all suffered a complete injury to the thoracic (chest-level) spinal cord. In a complete injury, there is no neurological function below the level of injury. All three patients were transplanted four to nine months after injury with a dose of 20 million cells at the site of injury. The surgery, immunosuppression and the cell transplants have been well tolerated by all the patients.

There were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first six months following transplantation. Changes in sensitivity to touch, heat and electrical stimuli were observed in well-defined and consistent areas below the level of injury in two of the patients, while no changes were observed in the third patient, the company said.

Importantly, tests of perception of different sensory stimuli as well as measures of electrical impulse transmission across the site of injury correlate with the clinical examination, providing independent and objective confirmation of the changes in sensory function.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Canadian gold miner IAMGOLD Corp. announced a strategic investment in Tradewind Markets, Inc., a financial technology company that uses blockchain to speed up and streamline digital gold trading. The miner did not elaborate on the investment amount, while Tradewind in its statement said it has closed a $10.6 million strategic placement. Bristol-Myers Squibb Co. (BMY) on Thursday increased adjusted earnings guidance for the full-year 2018 to a range of $3.35 to $3.45 per share from the prior range of $3.15 to $3.30 per share. However, the company lowered reported earnings outlook to a range of $2.70 to $2.80 per share from the previously... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported an increase in net income for the first quarter, reflecting higher revenues. Both adjusted earnings per share and net revenues for the quarter beat analysts' estimates. The company also reaffirmed its earnings and revenue outlook for...
Follow RTT